首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma
【24h】

A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma

机译:一种中性脂质包膜型纳米粒子,由pH活化和维生素E支架脂质样物质组成,作为靶向肾细胞癌的基因载体的平台

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A renal cell carcinoma (RCC) is one of the refractory tumors, since it readily acquires resistance against chemotherapy. Thus, alternative therapeutic approaches such as obstructing the neovasculature are needed. We previously reported on the development of a plasmid DNA (pDNA)-encapsulating liposomal nanoparticle (LNP) as a hepatic gene delivery system that is applicable to systemic administration. The key molecular component is a SS-cleavable and pH-activated lipid-like material (ssPalm) that mounts dual sensing motifs (ternary amines and disulfide bonding) that are responsive to the intracellular environment. The main purpose of the present study was to expand its application to a tumor-targeting gene delivery systemin mice bearing tumors established from a RCC (OS-RC-2). When the modification of the surface of the particle is optimized for the polyethyleneglycol (PEG), stability in the blood circulation is improved, and consequently tumor-selective gene expression can be achieved. Furthermore, gene expression in the tumor was increased slightly when the hydrophobic scaffold of the ssPalm was replaced from the conventionally used myristic acid (ssPalmM) to alpha-tocopherol succinate (ssPalmE). Moreover, tumor growth was significantly suppressed when the completely CpG-free pDNA encoding the solute form of VEGFR (fms-like tyrosine kinase-1: sFlt-1) was used, especially when it was delivered by the LNP formed with ssPalmE(LNPssPalmE). Thus, the PEG-modified LNPssPalmE is a promising gene carrier for the cancer gene therapy of RCC. (C) 2014 Elsevier B.V. All rights reserved.
机译:肾细胞癌(RCC)是难治性肿瘤之一,因为它很容易获得对化学疗法的抵抗力。因此,需要诸如阻塞新脉管系统的替代治疗方法。我们先前曾报道过质粒DNA(pDNA)封装脂质体纳米颗粒(LNP)作为肝基因传递系统的发展,适用于全身给药。关键分子成分是SS可裂解且pH激活的脂质样材料(ssPalm),其安装了对细胞内环境有响应的双重感应基元(三元胺和二硫键)。本研究的主要目的是将其应用扩展到携带由RCC(OS-RC-2)建立的肿瘤的小鼠的肿瘤靶向基因递送系统。当针对聚乙二醇(PEG)优化颗粒表面的修饰时,血液循环中的稳定性得到改善,因此可以实现肿瘤选择性基因表达。此外,当将ssPalm的疏水性支架从常规使用的肉豆蔻酸(ssPalmM)替换为α-生育酚琥珀酸酯(ssPalmE)时,肿瘤中的基因表达略有增加。此外,当使用完全无CpG的编码VEGFR的溶质形式的fpDNA(fms样酪氨酸激酶-1:sFlt-1)时,肿瘤的生长被显着抑制,特别是当它由与ssPalmE(LNPssPalmE)形成的LNP传递时。因此,PEG修饰的LNPssPalmE是用于RCC的癌症基因治疗的有前途的基因载体。 (C)2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号